

# Jerome de Seze

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5840243/publications.pdf>

Version: 2024-02-01

278  
papers

24,717  
citations

12303

69  
h-index

8138

148  
g-index

323  
all docs

323  
docs citations

323  
times ranked

16291  
citing authors

#	ARTICLE	IF	CITATIONS
1	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2015, 85, 177-189.	1.5	3,275
2	A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2010, 362, 387-401.	13.9	2,314
3	Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2012, 367, 1087-1097.	13.9	1,161
4	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012, 380, 1829-1839.	6.3	1,040
5	Neurologic Manifestations in Primary Sjögren Syndrome. <i>Medicine (United States)</i> , 2004, 83, 280-291.	0.4	536
6	MRI characteristics of neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2015, 84, 1165-1173.	1.5	523
7	Neuromyelitis Optica and Non-Organ-Specific Autoimmunity. <i>Archives of Neurology</i> , 2008, 65, 78-83.	4.9	497
8	Tibial Muscular Dystrophy Is a Titinopathy Caused by Mutations in TTN, the Gene Encoding the Giant Skeletal-Muscle Protein Titin. <i>American Journal of Human Genetics</i> , 2002, 71, 492-500.	2.6	408
9	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. <i>Neurology</i> , 2018, 90, e1858-e1869.	1.5	401
10	Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. <i>New England Journal of Medicine</i> , 2019, 381, 2114-2124.	13.9	383
11	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2016, 387, 1075-1084.	6.3	379
12	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020, 383, 546-557.	13.9	358
13	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1079.	4.5	357
14	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology, The</i> , 2021, 20, 762-772.	4.9	261
15	Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event. <i>PLoS ONE</i> , 2014, 9, e90509.	1.1	254
16	MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1719-1731.	1.4	249
17	Treatment of neuromyelitis optica: Review and recommendations. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 180-187.	0.9	217
18	Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2015, 21, 678-688.	1.4	209

#	ARTICLE	IF	CITATIONS
19	Neuromyelitis optica in France. <i>Neurology</i> , 2010, 74, 736-742.	1.5	196
20	Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases. <i>Brain</i> , 2001, 124, 1509-1521.	3.7	193
21	Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis: [RETIRED]. <i>Neurology</i> , 2011, 77, 2128-2134.	1.5	192
22	Association Between Clinical Conversion to Multiple Sclerosis in Radiologically Isolated Syndrome and Magnetic Resonance Imaging, Cerebrospinal Fluid, and Visual Evoked Potential. <i>Archives of Neurology</i> , 2009, 66, 841.	4.9	191
23	Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2007, 13, 256-259.	1.4	190
24	Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. <i>Journal of the Neurological Sciences</i> , 2002, 197, 57-61.	0.3	182
25	Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis. <i>Journal of Immunology</i> , 2009, 183, 4067-4076.	0.4	182
26	Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg's syndrome) enrolled in two prospective trials. <i>Journal of Autoimmunity</i> , 2013, 43, 60-69.	3.0	168
27	MS disease activity in RESTORE. <i>Neurology</i> , 2014, 82, 1491-1498.	1.5	166
28	Aquaporin-4 antibody-negative neuromyelitis optica. <i>Neurology</i> , 2013, 80, 2194-2200.	1.5	157
29	Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. <i>Multiple Sclerosis Journal</i> , 2014, 20, 843-847.	1.4	154
30	Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients. <i>Neurology</i> , 2007, 69, 953-958.	1.5	152
31	Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. <i>Lancet Neurology</i> , The, 2012, 11, 420-428.	4.9	152
32	Idiopathic acute transverse myelitis: Application of the recent diagnostic criteria. <i>Neurology</i> , 2005, 65, 1950-1953.	1.5	149
33	Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 922-930.	0.9	149
34	Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. <i>Journal of Neuroinflammation</i> , 2015, 12, 46.	3.1	149
35	Acute Fulminant Demyelinating Disease. <i>Archives of Neurology</i> , 2007, 64, 1426.	4.9	148
36	Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy. <i>Brain</i> , 2012, 135, 2980-2993.	3.7	148

#	ARTICLE	IF	CITATIONS
37	Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1067-1073.	1.4	144
38	Switching From Natalizumab to Fingolimod in Multiple Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 436.	4.5	133
39	Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 132-136.	0.9	132
40	Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 521-525.	1.4	131
41	Is neuromyelitis optica associated with human leukocyte antigen?. <i>Multiple Sclerosis Journal</i> , 2009, 15, 571-579.	1.4	122
42	Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. <i>Cytokine</i> , 2009, 45, 55-57.	1.4	121
43	Cognitive function in radiologically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2010, 16, 919-925.	1.4	116
44	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 134.	3.1	115
45	Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 195-198.	0.9	112
46	Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	112
47	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197.	4.9	110
48	Long-term Outcomes of CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2012, 69, 847-55.	4.9	109
49	NMO-IgG and Devic's neuromyelitis optica: a French experience. <i>Multiple Sclerosis Journal</i> , 2008, 14, 440-445.	1.4	107
50	Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1135-1143.	1.4	107
51	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e134.	3.1	104
52	Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases. <i>Brain</i> , 2009, 132, 2161-2169.	3.7	103
53	Increased risk of multiple sclerosis relapse after in vitro fertilisation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 796-802.	0.9	102
54	Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 399-405.	1.4	101

#	ARTICLE	IF	CITATIONS
55	Cognitive Functions in Neuromyelitis Optica. <i>Archives of Neurology</i> , 2008, 65, 84-8.	4.9	98
56	Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 2012, 69, 1259.	4.9	97
57	Optical Coherence Tomography in Neuromyelitis Optica. <i>Archives of Neurology</i> , 2008, 65, 920-3.	4.9	96
58	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1377-1384.	1.4	89
59	Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 596-597.	1.4	88
60	Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1086-1094.	1.4	87
61	White Matter Atrophy and Cognitive Dysfunctions in Neuromyelitis Optica. <i>PLoS ONE</i> , 2012, 7, e33878.	1.1	85
62	CSF isoelectrofocusing in a large cohort of MS and other neurological diseases. <i>European Journal of Neurology</i> , 2004, 11, 525-529.	1.7	83
63	Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1409-1412.	0.9	82
64	Suicidal ideation in Huntington disease: The role of comorbidity. <i>Psychiatry Research</i> , 2011, 188, 372-376.	1.7	82
65	Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1344-1350.	0.9	80
66	Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. <i>Autoimmunity Reviews</i> , 2014, 13, 197-205.	2.5	77
67	Current and future treatment approaches for neuromyelitis optica. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 111-121.	1.5	73
68	Comparative efficacy of fingolimod vs natalizumab. <i>Neurology</i> , 2016, 86, 771-778.	1.5	71
69	Guillain-Barre Syndrome, Influenzalike Illnesses, and Influenza Vaccination During Seasons With and Without Circulating A/H1N1 Viruses. <i>American Journal of Epidemiology</i> , 2011, 174, 326-335.	1.6	69
70	Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France. <i>Multiple Sclerosis Journal</i> , 2020, 26, 118-122.	1.4	69
71	Prospective study of patients presenting with acute partial transverse myelopathy. <i>Journal of Neurology</i> , 2003, 250, 1447-1452.	1.8	67
72	Multiple sclerosis and depression: influence of interferon b therapy. <i>Multiple Sclerosis Journal</i> , 2003, 9, 284-288.	1.4	67

#	ARTICLE	IF	CITATIONS
73	New antigenic candidates in multiple sclerosis: Identification by serological proteome analysis. <i>Proteomics</i> , 2004, 4, 2184-2194.	1.3	67
74	Quality of life in multiple sclerosis: influence of interferon- $\beta$ 1a (Avonex <sup>®</sup> ) treatment. <i>Multiple Sclerosis Journal</i> , 2002, 8, 377-381.	1.4	66
75	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. <i>Neurology</i> , 2017, 89, 1584-1593.	1.5	65
76	Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. <i>Journal of the Neurological Sciences</i> , 2004, 218, 73-77.	0.3	63
77	Acute limbic encephalitis and glutamic acid decarboxylase antibodies: A reality?. <i>Journal of the Neurological Sciences</i> , 2009, 287, 69-71.	0.3	63
78	Rituximab in refractory and non-refractory myasthenia: A retrospective multicenter study. <i>Muscle and Nerve</i> , 2012, 46, 687-691.	1.0	63
79	Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. <i>Neurology</i> , 2015, 84, 1145-1152.	1.5	63
80	JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. <i>Multiple Sclerosis Journal</i> , 2014, 20, 822-829.	1.4	62
81	Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica. <i>European Journal of Neurology</i> , 2011, 18, 836-841.	1.7	61
82	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. <i>Journal of Neurology</i> , 2016, 263, 140-149.	1.8	60
83	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815.	4.5	59
84	New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. <i>Immunology Letters</i> , 2005, 96, 11-26.	1.1	58
85	Adult-onset genetic leukoencephalopathies: A MRI pattern-based approach in a comprehensive study of 154 patients. <i>Brain</i> , 2015, 138, 284-292.	3.7	58
86	Autonomic dysfunction in multiple sclerosis: cervical spinal cord atrophy correlates. <i>Journal of Neurology</i> , 2001, 248, 297-303.	1.8	57
87	RELAPSING INFLAMMATORY OPTICNEURITIS: IS IT NEUROMYELITIS OPTICA?. <i>Neurology</i> , 2008, 70, 2075-2076.	1.5	56
88	Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2010, 292, 28-35.	0.3	56
89	Air pollution by particulate matter PM10 may trigger multiple sclerosis relapses. <i>Environmental Research</i> , 2017, 156, 404-410.	3.7	56
90	OFSEP, a nationwide cohort of people with multiple sclerosis: Consensus minimal MRI protocol. <i>Journal of Neuroradiology</i> , 2015, 42, 133-140.	0.6	55

#	ARTICLE	IF	CITATIONS
91	Efficacy of rituximab in refractory neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2016, 22, 955-959.	1.4	55
92	Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. <i>Arthritis and Rheumatism</i> , 2007, 56, 3420-3432.	6.7	54
93	A Benign Form of Neuromyelitis Optica. <i>Archives of Neurology</i> , 2011, 68, 918.	4.9	54
94	Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1297-1302.	1.4	53
95	Relapsing demyelinating disease affecting both the central and peripheral nervous systems. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1032-1039.	0.9	52
96	Long-term outcome of acute and subacute myelopathies. <i>Journal of Neurology</i> , 2009, 256, 980-988.	1.8	52
97	Magnetic resonance spectroscopy evaluation in patients with neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 409-411.	0.9	52
98	Cancer and multiple sclerosis in the era of disease-modifying treatments. <i>Journal of Neurology</i> , 2011, 258, 1304-1311.	1.8	52
99	Autophagy in neuroinflammatory diseases. <i>Autoimmunity Reviews</i> , 2017, 16, 856-874.	2.5	50
100	Ozone, NO <sub>2</sub> and PM <sub>10</sub> are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses. <i>Environmental Research</i> , 2018, 163, 43-52.	3.7	50
101	Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options. <i>Drugs</i> , 2019, 79, 125-142.	4.9	50
102	Association of multiple sclerosis with ILT6 deficiency. <i>Genes and Immunity</i> , 2005, 6, 445-447.	2.2	49
103	Autonomic and respiratory dysfunction in Charcot-Marie-Tooth disease due to Thr124Met mutation in the myelin protein zero gene. <i>Clinical Neurophysiology</i> , 2003, 114, 1609-1614.	0.7	48
104	Immunological profiles determine neurological involvement in Sjögren's syndrome. <i>European Journal of Internal Medicine</i> , 2014, 25, 177-181.	1.0	48
105	Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. <i>PLoS ONE</i> , 2015, 10, e0132033.	1.1	48
106	Distortion of the Self-Reactive IgG Antibody Repertoire in Multiple Sclerosis as a New Diagnostic Tool. <i>Journal of Immunology</i> , 2004, 172, 669-678.	0.4	47
107	White matter volume is decreased in the brain of patients with neuromyelitis optica. <i>European Journal of Neurology</i> , 2013, 20, 361-367.	1.7	47
108	An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 180-188.	1.5	47

#	ARTICLE	IF	CITATIONS
109	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. <i>Journal of Neurology</i> , 2019, 266, 806-815.	1.8	47
110	Retinal Optical Coherence Tomography in Neuromyelitis Optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	47
111	Patient perceptions of multiple sclerosis and its treatment. <i>Patient Preference and Adherence</i> , 2012, 6, 263.	0.8	46
112	IgG reactivity against citrullinated myelin basic protein in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2001, 117, 149-155.	1.1	45
113	Lyme Neuroborreliosis and Dementia. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 1087-1093.	1.2	45
114	Autoimmune hepatitis and multiple sclerosis: a coincidental association?. <i>Multiple Sclerosis Journal</i> , 2005, 11, 691-693.	1.4	44
115	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. <i>Lancet Neurology</i> , The, 2022, 21, 608-619.	4.9	44
116	Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. <i>Multiple Sclerosis Journal</i> , 2010, 16, 87-92.	1.4	43
117	Combination of IFN-1a (Avonex <sup>®</sup> 1/2) and mycophenolate mofetil (Cellcept <sup>®</sup> 1/2) in multiple sclerosis. <i>European Journal of Neurology</i> , 2007, 14, 85-89.	1.7	42
118	Long-term Follow-up of Acute Partial Transverse Myelitis. <i>Archives of Neurology</i> , 2012, 69, 357.	4.9	42
119	Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. <i>Journal of the Neurological Sciences</i> , 2016, 363, 69-76.	0.3	42
120	Unusual ocular motor findings in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2006, 243, 91-95.	0.3	41
121	Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. <i>Journal of Neurology</i> , 2010, 257, 207-211.	1.8	41
122	Relapsing optic neuritis: a multicentre study of 62 patients. <i>Multiple Sclerosis Journal</i> , 2014, 20, 848-853.	1.4	41
123	Radiologically isolated syndrome in children. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e395.	3.1	41
124	Lyme optic neuritis. <i>Journal of the Neurological Sciences</i> , 2010, 295, 117-119.	0.3	40
125	Visual evoked potentials study in chronic idiopathic inflammatory demyelinating polyneuropathy. <i>Clinical Neurophysiology</i> , 2000, 111, 2285-2291.	0.7	39
126	Pupillary disturbances in multiple sclerosis: correlation with MRI findings. <i>Journal of the Neurological Sciences</i> , 2001, 188, 37-41.	0.3	39



#	ARTICLE	IF	CITATIONS
127	Challenges and opportunities in designing clinical trials for neuromyelitis optica. <i>Neurology</i> , 2015, 84, 1805-1815.	1.5	39
128	Vocal cord and diaphragm paralysis, as clinical features of a French family with autosomal recessive Charot-Marie-Tooth disease, associated with a new mutation in the GDAP1 gene. <i>Neuromuscular Disorders</i> , 2004, 14, 261-264.	0.3	38
129	Serum analysis by <sup>1</sup> H Nuclear Magnetic Resonance spectroscopy: a new tool for distinguishing neuromyelitis optica from multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 558-565.	1.4	38
130	Diffusion-weighted imaging in noncompressive myelopathies: a 33-patient prospective study. <i>Journal of Neurology</i> , 2010, 257, 1438-1445.	1.8	37
131	A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The <sc>BIONAT</sc> cohort. <i>European Journal of Neurology</i> , 2014, 21, 40-48.	1.7	37
132	Clinical Spectrum and Treatment of Neuromyelitis Optica Spectrum Disorders: Evolution and Current Status. <i>Brain Pathology</i> , 2013, 23, 647-660.	2.1	36
133	Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. <i>Neurology</i> , 2019, 93, e635-e646.	1.5	36
134	Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	36
135	Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. <i>Journal of Neurology</i> , 2012, 259, 2293-2298.	1.8	34
136	Central nervous system abnormalities in patients with PMP22 gene mutations: a prospective study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 392-397.	0.9	34
137	Prior suggestive symptoms in one-third of patients consulting for a "first" demyelinating event. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 323-325.	0.9	33
138	POLG1 Variations Presenting as Multiple Sclerosis. <i>Archives of Neurology</i> , 2010, 67, 1140-3.	4.9	32
139	Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. <i>JAMA Network Open</i> , 2021, 4, e2128271.	2.8	32
140	One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 360-363.	1.4	31
141	Induced Brain Plasticity after a Facilitation Programme for Autobiographical Memory in Multiple Sclerosis: A Preliminary Study. <i>Multiple Sclerosis International</i> , 2012, 2012, 1-12.	0.4	31
142	Multiple sclerosis, interferon beta and clinical thyroid dysfunction. <i>Acta Neurologica Scandinavica</i> , 2003, 107, 154-157.	1.0	30
143	Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 279-283.	0.9	30
144	Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis. <i>CNS Drugs</i> , 2016, 30, 41-51.	2.7	29

#	ARTICLE	IF	CITATIONS
145	Silver stained isoelectrophoresis of tears and cerebrospinal fluid in multiple sclerosis. <i>Journal of Neurology</i> , 2001, 248, 672-675.	1.8	28
146	Phrenic nerve palsy as a feature of chronic inflammatory demyelinating polyradiculoneuropathy. <i>Muscle and Nerve</i> , 2003, 27, 497-499.	1.0	28
147	Letter to the editor. <i>Multiple Sclerosis Journal</i> , 2004, 10, 92-92.	1.4	27
148	14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis. <i>Journal of Neurology</i> , 2002, 249, 626-627.	1.8	26
149	Neuromyelitis Optica. <i>Archives of Neurology</i> , 2003, 60, 1336-8.	4.9	26
150	Autobiographical memory in multiple sclerosis patients: Assessment and cognitive facilitation. <i>Neuropsychological Rehabilitation</i> , 2013, 23, 161-181.	1.0	26
151	Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2006, 179, 53-64.	1.1	25
152	Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2017, 12, e0168834.	1.1	25
153	Paroxysmal kinesigenic choreoathetosis as a presenting symptom of multiple sclerosis. <i>Journal of Neurology</i> , 2000, 247, 478-480.	1.8	24
154	Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. <i>Clinical Immunology</i> , 2011, 138, 239-246.	1.4	24
155	Diffusion tensor imaging of normal-appearing white matter in neuromyelitis optica. <i>Journal of Neuroradiology</i> , 2012, 39, 295-300.	0.6	24
156	Longitudinal follow-up of vision in a neuromyelitis optica cohort. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1320-1322.	1.4	24
157	Using mental visual imagery to improve autobiographical memory and episodic future thinking in relapsing-remitting multiple sclerosis patients: A randomised-controlled trial study. <i>Restorative Neurology and Neuroscience</i> , 2015, 33, 621-638.	0.4	24
158	Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study. <i>Journal of Neurology</i> , 2015, 262, 1637-1645.	1.8	24
159	Pathologic laughing and intractable hiccups can occur early in multiple sclerosis. <i>Neurology</i> , 2006, 67, 1684-1686.	1.5	23
160	Foreign accent syndrome as a first sign of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1123-1125.	1.4	23
161	Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome. <i>Revue Neurologique</i> , 2015, 171, 390-393.	0.6	23
162	An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies. <i>Journal of Autoimmunity</i> , 2018, 92, 114-125.	3.0	23

#	ARTICLE	IF	CITATIONS
163	Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731983666.	0.5	23
164	Double-blind crossover study with dolasetron mesilate, a 5-HT 3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. <i>Journal of Neurology</i> , 2003, 250, 1190-1194.	1.8	22
165	Heroin inhalation-induced unilateral complete hippocampal stroke. <i>Neurocase</i> , 2013, 19, 313-315.	0.2	22
166	Reduction of the washout time between natalizumab and fingolimod. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1248-1248.	1.4	22
167	Evaluation of Clinical Interest of Anti-Aquaporin-4 Autoantibody Followup in Neuromyelitis Optica. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-7.	3.3	22
168	Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder. <i>Neurology</i> , 2021, 96, e2006-e2015.	1.5	22
169	Sequential magnetic resonance imaging follow-up of multiple sclerosis before the clinical phase. <i>Multiple Sclerosis Journal</i> , 2005, 11, 395-397.	1.4	21
170	Robotic-assisted thymectomy with Da Vinci II versus sternotomy in the surgical treatment of non-thymomatous myasthenia gravis: Early results. <i>Revue Neurologique</i> , 2013, 169, 30-36.	0.6	21
171	Dalfampridine in hereditary spastic paraplegia: a prospective, open study. <i>Journal of Neurology</i> , 2015, 262, 1285-1288.	1.8	21
172	Inflammatory Optic Neuritis: From Multiple Sclerosis to Neuromyelitis Optica. <i>Neuro-Ophthalmology</i> , 2013, 37, 141-145.	0.4	20
173	Cognitive Dysfunction and Dementia in Primary Sjögren's Syndrome. <i>ISRN Neurology</i> , 2013, 2013, 1-7.	1.5	20
174	Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. <i>Journal of Neurology</i> , 2015, 262, 326-336.	1.8	20
175	Serum-based differentiation between multiple sclerosis and amyotrophic lateral sclerosis by Random Forest classification of FTIR spectra. <i>Analyst</i> , 2019, 144, 4647-4652.	1.7	20
176	Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2012, 259, 1215-1221.	1.8	19
177	Mycophenolate mofetil and neurological diseases. <i>Lupus</i> , 2005, 14, 42-45.	0.8	18
178	Brain MRI findings in long-standing and disabling multiple sclerosis in 84 patients. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 286-290.	0.6	17
179	High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. <i>Multiple Sclerosis Journal</i> , 2011, 17, 720-724.	1.4	17
180	Atypical forms of optic neuritis. <i>Revue Neurologique</i> , 2012, 168, 697-701.	0.6	17

#	ARTICLE	IF	CITATIONS
181	Impaired mental simulation of specific past and future personal events in non-depressed multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2014, 345, 68-74.	0.3	17
182	Multiple sclerosis and pregnancy. <i>Revue Neurologique</i> , 2014, 170, 247-265.	0.6	17
183	Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 699-705.	0.9	16
184	Inflammatory-like presentation of CADASIL: a diagnostic challenge. <i>BMC Neurology</i> , 2012, 12, 78.	0.8	16
185	Review of animal models of neuromyelitis optica. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 174-179.	0.9	16
186	Extensive cerebral white matter involvement in a patient with NMO spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1401-1403.	1.4	16
187	Functional and structural cerebral changes in key brain regions after a facilitation programme for episodic future thought in relapsing-remitting multiple sclerosis patients. <i>Brain and Cognition</i> , 2016, 105, 34-45.	0.8	16
188	Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies. <i>Journal of Neuroimmunology</i> , 2015, 278, 1-10.	1.1	15
189	Exploratory Phase II Trial to Evaluate the Safety and the Antiepileptic Effect of Pitolisant (BF2.649) in Refractory Partial Seizures, Given as Adjunctive Treatment During 3 Months. <i>Clinical Neuropharmacology</i> , 2016, 39, 188-193.	0.2	15
190	Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAKuraSky and SAKuraStar. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 66, 104025.	0.9	15
191	Benefits from an autobiographical memory facilitation programme in relapsing-remitting multiple sclerosis patients: a clinical and neuroimaging study. <i>Neuropsychological Rehabilitation</i> , 2018, 28, 1110-1130.	1.0	14
192	Cardiac repolarization abnormalities in multiple sclerosis: Spinal cord MRI correlates. <i>Muscle and Nerve</i> , 2000, 23, 1284-1286.	1.0	13
193	Atypical form of non-Langerhans histiocytosis with disseminated brain and leptomeningeal lesions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 675-678.	0.9	13
194	Methionine synthase deficiency: A rare cause of adult-onset leukoencephalopathy. <i>Neurology</i> , 2012, 79, 386-388.	1.5	13
195	&lt;b>&lt;i>OPA3&lt;/i>&lt;/b>-Related Autosomal Dominant Optic Atrophy and Cataract with Ataxia and Areflexia. <i>European Neurology</i> , 2012, 68, 108-110.	0.6	13
196	Neural correlates of episodic future thinking impairment in multiple sclerosis patients. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2015, 37, 1107-1123.	0.8	13
197	False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1231-1234.	1.4	13
198	Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies. <i>Journal of Neuroinflammation</i> , 2020, 17, 128.	3.1	13

#	ARTICLE	IF	CITATIONS
199	How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103076.	0.9	13
200	Man-in-the-barrel syndrome caused by a pontine lesion. <i>Neurology</i> , 2005, 64, 1703-1703.	1.5	12
201	The Brown Norway optospinal model of demyelination: Does it mimic multiple sclerosis or neuromyelitis optica?. <i>International Journal of Developmental Neuroscience</i> , 2012, 30, 487-497.	0.7	12
202	PET follow-up in a case of anti-NMDAR encephalitis: arguments for cingulate limbic encephalitis. <i>Epileptic Disorders</i> , 2012, 14, 90-93.	0.7	12
203	Giving meaning to illness: An investigation of self-defining memories in patients with relapsing-remitting multiple sclerosis patients. <i>Consciousness and Cognition</i> , 2016, 45, 200-209.	0.8	12
204	Natalizumab-PML survivors with subsequent MS treatment. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e346.	3.1	12
205	An A Contrario Approach for Change Detection in 3D Multimodal Images: Application to Multiple Sclerosis in MRI. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society</i> , 2007, 2007, 2069-72.	0.5	11
206	Primary progressive multiple sclerosis: a comparative study of the diagnostic criteria. <i>Multiple Sclerosis Journal</i> , 2007, 13, 622-625.	1.4	11
207	Longitudinal change detection in diffusion MRI using multivariate statistical testing on tensors. <i>NeuroImage</i> , 2012, 60, 2206-2221.	2.1	11
208	Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement. <i>Revue Neurologique</i> , 2020, 176, 100-112.	0.6	11
209	Serum IgG repertoire in clinically isolated syndrome predicts multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 593-600.	1.4	10
210	Novel <scp>SPG</scp>10 mutation associated with dysautonomia, spinal cord atrophy, and skin biopsy abnormality. <i>European Journal of Neurology</i> , 2013, 20, 398-401.	1.7	10
211	Recommendations for useful serum testing with suspected multiple sclerosis. <i>Revue Neurologique</i> , 2013, 169, 37-46.	0.6	10
212	Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 93-96.	0.9	10
213	MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease?. <i>Brain</i> , 2017, 140, 3072-3075.	3.7	10
214	Resting-state functional MRI demonstrates brain network reorganization in neuromyelitis optica spectrum disorder (NMOSD). <i>PLoS ONE</i> , 2019, 14, e0211465.	1.1	10
215	FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis. <i>Journal of Neuroinflammation</i> , 2019, 16, 54.	3.1	10
216	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020, 10, e035397.	0.8	10

#	ARTICLE	IF	CITATIONS
217	Interferon Î²1a (Avonex®) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability. <i>Journal of Neurology</i> , 2002, 249, 184-187.	1.8	9
218	A Case of Paraneoplastic Demyelinating Motor Polyneuropathy. <i>Case Reports in Neurology</i> , 2012, 4, 71-76.	0.3	9
219	Functional cerebral changes in multiple sclerosis patients during an autobiographical memory test. <i>Memory</i> , 2015, 23, 1123-1139.	0.9	9
220	Assessing Autophagy in Sciatic Nerves of a Rat Model that Develops Inflammatory Autoimmune Peripheral Neuropathies. <i>Cells</i> , 2017, 6, 30.	1.8	9
221	Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions. <i>Journal of Neurology</i> , 2019, 266, 1743-1755.	1.8	9
222	Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 109-116.	0.9	9
223	BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1556-1563.	1.4	9
224	Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort. <i>Multiple Sclerosis Journal</i> , 2021, 27, 729-741.	1.4	9
225	Evolution of self-reactive IgG antibody repertoires in patients with relapsing-remitting multiple sclerosis. <i>Immunology Letters</i> , 2005, 97, 55-62.	1.1	8
226	An a contrario approach for outliers segmentation: Application to Multiple Sclerosis in MRI. , 2008, , .		8
227	Severe and rapidly evolving peripheral neuropathy revealing sporadic Creutzfeldt-Jakob disease. <i>Journal of Neurology</i> , 2009, 256, 134-136.	1.8	8
228	Recommendations for the detection and therapeutic management of cognitive impairment in multiple sclerosis. <i>Revue Neurologique</i> , 2012, 168, 785-794.	0.6	8
229	Immunological follow-up of patients with neuromyelitis optica: Is there a good biomarker?. <i>Lupus</i> , 2013, 22, 229-232.	0.8	8
230	Evaluation of an albumin-binding gadolinium contrast agent in multiple sclerosis. <i>Neurology</i> , 2013, 81, 206-210.	1.5	8
231	Isolated anti-Î²2â€glycoprotein I antibodies in neurology: a frontier syndrome between multiple sclerosis and antiphospholipid syndrome?. <i>European Journal of Neurology</i> , 2014, 21, 901-906.	1.7	8
232	Emotional disturbances in multiple sclerosis: A neuropsychological and fMRI study. <i>Cortex</i> , 2019, 117, 205-216.	1.1	8
233	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	2.7	8
234	Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study. <i>Journal of Neurology</i> , 2022, 269, 3295-3300.	1.8	8

#	ARTICLE	IF	CITATIONS
235	Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder. <i>Current Opinion in Neurology</i> , 2019, 32, 111-114.	1.8	7
236	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103080.	0.9	7
237	The diagnosis of chronic inflammatory demyelinating polyneuropathy: a Delphi-method approach. <i>Journal of Neurology</i> , 2013, 260, 3015-3022.	1.8	6
238	MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103164.	0.9	6
239	Molecular Analysis of Endogenous Retrovirus HRES-1: Identification of Frameshift Mutations in Region Encoding Putative 28-kDa Autoantigen. <i>Biochemical and Biophysical Research Communications</i> , 2001, 283, 437-444.	1.0	5
240	Determination of interferon beta neutralizing antibodies in multiple sclerosis: Improvement of clinical sensitivity of a cytopathic effect assay. <i>Clinica Chimica Acta</i> , 2008, 391, 98-101.	0.5	5
241	Evaluation of new immunological targets in neuromyelitis optica. <i>Journal of Peptide Science</i> , 2013, 19, 25-32.	0.8	5
242	Longitudinal change detection: Inference on the diffusion tensor along white matter pathways. <i>Medical Image Analysis</i> , 2013, 17, 375-386.	7.0	5
243	Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE. <i>Joint Bone Spine</i> , 2016, 83, 330-334.	0.8	5
244	Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications. <i>Current Treatment Options in Neurology</i> , 2017, 19, 19.	0.7	5
245	Good therapeutic response to infliximab in a case of Susac syndrome refractory to immunotherapies including tocilizumab. <i>Journal of Neurology</i> , 2022, 269, 3347-3350.	1.8	5
246	Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing/Remitting Multiple Sclerosis After Fingolimod Withdrawal. <i>Neurotherapeutics</i> , 2022, 19, 476-490.	2.1	5
247	A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis. <i>Neurology and Therapy</i> , 2022, 11, 981-1042.	1.4	5
248	Case 173: Acute Disseminated Encephalomyelitis Confined to the Brainstem. <i>Radiology</i> , 2011, 260, 911-914.	3.6	4
249	Asthma as a Cause of Persistent Dyspnea in Treated Myasthenia Gravis Patients. <i>European Neurology</i> , 2012, 68, 300-303.	0.6	4
250	Recommendations for the management of multiple sclerosis relapses. <i>Revue Neurologique</i> , 2012, 168, 425-433.	0.6	4
251	Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 979-986.	1.3	4
252	A Case of Recurrent Facial Pain Associated With a <sc>P</sc>ourfour du <sc>P</sc>etit Syndrome: A New Entity?. <i>Headache</i> , 2014, 54, 373-377.	1.8	4

#	ARTICLE	IF	CITATIONS
253	Inadequate Immune Humoral Response against JC Virus in Progressive Multifocal Leukoencephalopathy Non-Survivors. <i>Viruses</i> , 2020, 12, 1380.	1.5	4
254	Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. <i>Journal of Neuroradiology</i> , 2021, 48, 170-175.	0.6	4
255	Emotional experience is increased and emotion recognition decreased in multiple sclerosis. <i>Scientific Reports</i> , 2021, 11, 21885.	1.6	4
256	Rapid Discrimination of Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Using Machine Learning on Infrared Spectra of Sera. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2791.	1.8	4
257	Obstructive sleep apnoea: an underestimated cause of peripheral neuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 222-222.	0.9	3
258	Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis. <i>BMC Neurology</i> , 2014, 14, 215.	0.8	3
259	Chronic Bickerstaff's encephalitis with cognitive impairment, a reality?. <i>BMC Neurology</i> , 2014, 14, 99.	0.8	3
260	Distinct and common cerebral activation changes during mental time travel in relapsing-remitting multiple sclerosis patients. <i>Brain Imaging and Behavior</i> , 2016, 10, 296-313.	1.1	3
261	Interferon beta in multiple sclerosis: relationship between sustained serum IgG levels and clinical outcome. <i>Journal of Neuroimmunology</i> , 2002, 129, 232-236.	1.1	2
262	Recommendations for a definition of multiple sclerosis in support of early treatment. <i>Revue Neurologique</i> , 2012, 168, 328-337.	0.6	2
263	Targeted clinical audits immediately following the establishment of clinical practice guidelines for multiple sclerosis in 17 neurology departments: A pragmatic and collaborative study. <i>Revue Neurologique</i> , 2015, 171, 407-414.	0.6	2
264	CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention. <i>Immuno</i> , 2022, 2, 118-131.	0.6	2
265	Multiple sclerosis with normal neuro-ophthalmological work-up: results of focal stimulations induced by a scanning laser ophthalmoscope. <i>Acta Neurologica Scandinavica</i> , 2000, 101, 311-314.	1.0	1
266	Thérapeutiques et prise en charge de la sclérose en plaques. , 2017, , 145-216.		1
267	Longitudinal Change Detection: Inference on the Diffusion Tensor Along White-Matter Pathways. <i>Lecture Notes in Computer Science</i> , 2011, 14, 1-8.	1.0	1
268	Monophasic Acute, Recurrent, and Multiphasic Disseminated Encephalomyelitis and Multiple Sclerosis—Reply. <i>Archives of Neurology</i> , 2008, 65, 672.	4.9	0
269	Differential Diagnosis Between Acute Disseminated Encephalomyelitis and Multiple Sclerosis During the First Episode—Reply. <i>Archives of Neurology</i> , 2008, 65, 672.	4.9	0
270	Multiple Sclerosis and Recurrent Disseminated Encephalomyelitis Are Different Diseases—Reply. <i>Archives of Neurology</i> , 2008, 65, 672.	4.9	0



#	ARTICLE	IF	CITATIONS
271	Prise en charge thérapeutique des manifestations neuropsychiatriques du lupus érythémateux. , 2013, , 265-271.		0
272	No evidence for genetic association between glutamate transporter EAAT2 and Devic's neuromyelitis optica in caucasians and afro-caribbeans. Multiple Sclerosis and Related Disorders, 2014, 3, 89-93.	0.9	0
273	Characterization of the humoral immune response in a Lewis rat model of CIDP. Journal of Neuroimmunology, 2014, 275, 115.	1.1	0
274	Diagnostics différentiels de la sclérose en plaques. , 2017, , 113-143.		0
275	Signes et symptômes de la sclérose en plaques. , 2017, , 3-78.		0
276	Overview of treatment of NMO. Acta Ophthalmologica, 2014, 92, 0-0.	0.6	0
277	Antibodies, MRI and unusual clinical features of NMO. Acta Ophthalmologica, 2014, 92, 0-0.	0.6	0
278	Diagnostic positif de la sclérose en plaques. , 2017, , 79-111.		0